PsychoGenics’ Post

Excited to announce that PsychoGenics will be at the Society for Neuroscience (SfN) 2024 Annual Meeting! 🧠🔬 Visit us at booth #325 to learn about our cutting-edge work in Neurodegeneration, Abuse Liability, and Pain research. Don't miss our poster presentations: Utilizing rat kindling models for anti-epileptic drugs screening (B122, Oct 5) Parkinson's Disease: Molecular and Genetic Studies (C93, Oct 5) Comparison of rat models of vascular headache and trigeminal sensitization (C103, Oct 6) In vivo PK, side effect profile, and analgesic efficacy of multiple compounds (C150, Oct 6) Characterization of a SOD1 Rat Model of ALS (B103, Oct 6) Characterization of the Ube3a Mouse Model of Angelman Syndrome (A5, Oct 6) Evaluation of the abuse liability of gabapentin and duloxetine in rats (O12, Oct 8) Locomotor and sensory behavior changes in spinal cord injury model (D35, Oct 8) We're looking forward to sharing our latest findings and connecting with fellow neuroscience enthusiasts. See you there! #SfN2024 #Neuroscience #DrugDiscovery #PreclinicalResearch #PsychoGenics

Kindling models using electrical stimulation of the rat amygdala or hippocampus are providing valuable insights into seizure mechanisms and potential treatments. These models mimic temporal lobe epilepsy and focal seizures, a subject we explore in our recent blog post explores these models. Curious to learn more about how these models can advance your epilepsy research? Check out our full blog post. #EpilepsyResearch #Neuroscience #DrugDiscovery #PreclinicalModels

Exciting news! We're thrilled to announce that NIMH has awarded PsychoGenics a Fast Track SBIR grant of up to $3 million over four years! This fantastic opportunity will fuel our work using the eCube® platform - our cutting-edge AI-enabled EEG technology - to explore potential treatments for rare disorders. With millions affected by rare diseases worldwide, we're energized and ready to push the boundaries of AI-driven drug discovery to address this critical need. We can't wait to see where this research takes us. Stay tuned for updates! #RareDiseaseResearch #AIinDrugDiscovery #NIMHGrant #InnovationInAction https://lnkd.in/gJ9FDz_k

At PsychoGenics, we're committed to supporting neurodegenerative disease studies. Our new blog post examines the APP/PS1 mouse model, crucial for investigating Alzheimer's disease progression. This model, expressing mutated amyloid precursor protein and presenilin 1, provides valuable insights into amyloid pathology and neurodegeneration. See how this well-characterized model can benefit your Alzheimer's research: https://lnkd.in/eHTXkm9G #AlzheimersResearch #NeurodegenerativeDisease #CRO

At PsychoGenics, we're committed to providing researchers with well-characterized animal models. Our latest blog post explores the rTg4510 mouse model for Alzheimer's disease. Discover how this model can enhance your AD research. Read more: https://lnkd.in/eBWpq98X #AlzheimersResearch #DiseaseModels #Neuroscience

Exploring the R6/1 Mouse Model for Huntington's Disease Research Our latest blog post examines the R6/1 mouse model, a valuable tool for understanding Huntington's disease (HD) pathology, which exhibits: - Reduced body weight and grip strength in R6/1 mice - Significant declines in locomotor activity and rearing - Decreased striatal medium spiny neuron markers - Elevated NF-L, a marker of neuronal loss, in R6/1 cerebrospinal fluid - Extensive accumulation of mutant huntingtin aggregates in the striatum Read how Psychogenics is leveraging this model to advance Huntington's disease research: https://lnkd.in/eHGQd-Yr #HuntingtonsDisease #R61MouseModel #Neuroscience

PsychoGenics will be attending IASP 2024 World Congress on Pain in Amsterdam August 5-9, 2024! Stop by our posters and learn about our capabilities in pain Research:    Characterization of the Rat MIA Model of Osteoarthritis in Support of the NIH Preclinical Screening Platform for Pain (PSPP). Aug 6: 9:30 – 11:00 am Characterization of Rat Models of Headache in Support of the NIH Preclinical Screening Platform for Pain (PSPP). Aug 8: 9:30 – 11:00 am Effects of Synthetic Cannabidiol (CBD) Evaluated Within the NIH Preclinical Screening Platform for Pain (PSPP). Aug 8: 3:15 – 4:45 pm   For more information on our capabilities please contact us at info@psychogenics.com

🧠 Traumatic brain injury (TBI) is a silent epidemic, with the US CDC reporting around 190 American deaths from TBI daily. At PsychoGenics, we're dedicated to advancing TBI research through our work with the controlled cortical impact (CCI) model. This model helps us understand motor and cognitive deficits, inflammation, oxidative stress, cell death, apoptosis, and gliosis in the brain. Our goal is to uncover new insights and pave the way for effective treatments. Learn more➡ https://lnkd.in/ebs-6tzH

The PsychoGenics team is at the 41st annual Neurotrauma Symposium hosted by NNS - National Neurotrauma Society in San Francisco this week!   🤝 Connect with Johana and Taleen to view our research on neuroprotective therapies for traumatic brain injuries. 📧 To learn more, contact us at info@psychogenics.com! #neurotrauma #PsychoGenics #CNSResearch #Preclinical

🔬 Exploring ALS Research 🧠 Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease. Learn more about the characterization of the TDP-43 (ΔNLS) mouse model. This model exhibits key ALS-related symptoms, including elevated neurofilament light chain (NF-L) levels, progressive motor deficits, and changes in neuromuscular function. At PsychoGenics, we're committed to advancing our understanding of ALS and finding potential therapeutic interventions.